
Hosted by Russell LaMontagne, President and Chief Executive Officer
Boston Immune Technologies and Therapeutics.
Thursday 14th June | 5pm BST 9am PST
Can't make the date? Still register and the recording can be sent to you afterwards
Boston Immune Technologies and Therapeutics have made strides over the last few years in developing immune based approaches for the treatment of cancer and infectious diseases. From the oncology side, Russell and his team are developing a platform to target tumours with TNFR2 receptors, which target the immunosuppressive T Cells that protect tumours against checkpoint inhibitors.
Listen to his free live webinar and benefit from insights into:
- The role of TNFR2 tregs
- TNFR2 Oncogene
- Novel TNFR2 antibodies
Russell LaMontagneCo-Founder, President and CEO Russell has been senior advisor to biotechnology and pharmaceutical companies for over 20 years. He played a predominant role in the development of several early stage companies and has advised pharmaceutical companies regarding commercialization strategies. Russell is also co-founder of Endobiome, Inc.
Russell will also be presenting at the Advances in Immuno-Oncology USA Congress on 11-12 October 2018 in San Diego, USA.
The Congress will cover 2 interactive streams:
- Development of Immuno-Oncology Therapies
- Translational Immuno-Oncology and Clinical Development
And will be co-located with the 3rd Annual Biomarkers & Precision Medicine Congress